top of page

Alltrna raises $109 million in a Series B financing to advance tRNA based therapies

CEO Michelle Werner explains the science behind how Alltrna is trying to harness transfer RNA to develop therapies for stop codon disease.




Comentários


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page